ValueMay 4, 2026

Buy the Dip Monday: 121% ROIC, 49% Revenue Growth, and the Biotech at 7.6× Earnings

Top 5 Pixie Picks

This Week's Setup

Buying dips this week means pairing revenue growth with margin power, not chasing rebounds. PTCT doubled revenue while printing 121% ROIC and a 7.6 P/E, CNX grew revenue 49% with an 11% ROIC and 10% FCF yield, and INCY carries a 111% ROIC, 21% revenue growth, and a 93% gross margin at 13.6× earnings.

BANC trades below book with an 8.2% FCF yield, NEM delivers 30% ROIC with a 19% drawdown and 31% analyst upside, and FSLR sits 25% off peak despite 24% revenue growth and 17% ROIC.

The S&P 500 CAPE at 38.9 flags expensive broad-market multiples, making single-digit and low-teens P/E names with operational leverage the filtering lens.

Quick Scan

#	Ticker	One-line thesis
1	PTCT	115% revenue growth, 121% ROIC, 25% drawdown
2	FSLR	24% revenue growth, 17% ROIC, 25% drawdown
3	NEM	30% ROIC, 19% drawdown, 31% analyst upside
4	INCY	111% ROIC, 93% gross margin, 14% drawdown
5	CNX	49% revenue growth, 10% FCF yield, 13% drawdown
6	GSK	20% ROIC, 72% gross margin, 16% drawdown
7	AMAL	11% FCF yield, 8% earnings yield, 6% drawdown
8	BANC	8% FCF yield, 0.94× book, 14% drawdown

The 8 Names

1. PTC Therapeutics, Inc. (PTCT)

P/E: 7.6 | Earnings yield: 13.1% | 52w drawdown: 25.4%

Revenue doubled year-over-year, ROIC sits at 121%, and the company trades at 7.6× earnings with a 7.6% FCF yield. The setup here is a growth biotech priced like a value trap.

Golden Lee Scott, Klein Matthew, and Boulding Mark Elliott added net shares in April; 8.8% of insider transactions were buys. The company posted positive Huntington's disease trial results, expanding the pipeline thesis beyond the current commercial base.

Debt-to-equity is negative at -13.2, reflecting timing of cash flows and aggressive balance sheet structure; short interest is 11.7% of float, signaling skepticism on valuation sustainability.

2. First Solar, Inc. (FSLR)

P/E: 13.9 | Earnings yield: 7.2% | 52w drawdown: 24.5%

Revenue grew 24%, ROIC is 17%, and gross margin is 41%; the company posted record Q1 results and reaffirmed 2026 guidance. Analysts hold a $245 target against a $216 current price, implying 14% upside.

Short interest is 6.4% of float, and the stock sits 25% off its 52-week peak. Evercore raised its target to $219 but maintained an In Line rating, flagging valuation as fair rather than cheap.

Verma Kuntal Kumar added shares in mid-April. The solar sector is working through tariff uncertainty and module pricing pressure, making the drawdown a function of macro sentiment rather than operational weakness.

3. Newmont Corporation (NEM)

P/E: 14.2 | Earnings yield: 7.0% | 52w drawdown: 18.8%

ROIC is 30%, revenue grew 21%, and gross margin is 53%. The company authorized a $6 billion buyback and beat Q1 expectations, yet the stock dropped 10% on the news and trades 19% off peak. Analysts hold a $144 target against a $110 current price, implying 31% upside.

The market priced in the buyback and sold the news; the stock is up 42 basis points over the trailing year, underperforming the sector despite operational strength. Short interest is low at 1.8% of float.

Insiders added 8,092 net shares over the past six months; 2.4% of transactions were buys. The gold miner is generating cash at a 30% return on capital while trading at a material discount to analyst consensus, creating a margin-of-safety setup for patient holders.

4. Incyte Corporation (INCY)

P/E: 13.6 | Earnings yield: 7.4% | 52w drawdown: 14.3%

ROIC is 111%, revenue grew 21%, and gross margin is 93%. The FDA approved Jakafi XR for myelofibrosis, polycythemia vera, and graft-versus-host disease, broadening the commercial franchise beyond the original indication.

Meury William and CAGNONI PABLO J sold shares in April; 7.7% of insider transactions were buys, 10% were sells. Analysts reaffirmed ratings and positioned the company to offset patent cliff risks through pipeline and label expansion.

Normalized P/E over ten years is 35.9, well above the current 13.6 multiple, suggesting the market is pricing in structural margin compression or slower growth. Debt-to-equity is minimal at 0.8%, limiting balance sheet risk.

5. CNX Resources Corporation (CNX)

P/E: 5.0 | Earnings yield: 19.9% | 52w drawdown: 13.5%

Revenue grew 49%, ROIC is 11%, and FCF yield is 10%. The company trades at 5× earnings and 3.7× EV/EBITDA, pricing in no growth despite operational outperformance. Q1 results highlighted strong performance amid infrastructure and demand tailwinds.

Insiders added 383,371 net shares over six months; 7% of transactions were buys, 1.1% were sells. The insider-to-sell ratio is 5.3, signaling management conviction at current levels.

Short interest is 14.8% of float, the highest on this list, and the stock is trading lower post-earnings. Analysts hold a $38 target against a $38 current price, implying flat upside and skepticism on multiple expansion.

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Value stocks.

6. GSK plc (GSK)

P/E: 13.5 | Earnings yield: 7.4% | 52w drawdown: 16.0%

ROIC is 20%, gross margin is 72%, and the company completed a $950 million acquisition to expand its drug pipeline. The stock trades 16% off peak with a 3.5% dividend yield and analyst upside of 11% to a $58 target.

Revenue growth is 4.1%, the slowest on this list, and EV/EBITDA is 19.7, the highest valuation multiple among the eight names. The company is navigating an Alzheimer's setback and a leadership shift, creating near-term execution uncertainty.

Debt-to-equity is 1.17, the second-highest leverage ratio here. Normalized P/E over ten years is 15.1, close to the current 13.5 multiple, suggesting the market is pricing the company at steady-state rather than discount.

7. Amalgamated Financial Corp. (AMAL)

P/E: 12.2 | Earnings yield: 8.2% | 52w drawdown: 5.8%

FCF yield is 10.9%, the highest on this list, and the company trades at 1.5× book with a 1.5% dividend yield. Q1 deposit growth was the highlight, offsetting a profit miss and credit event.

Johnson Amal M, Searby Sean, and Tenner Mandy added shares in April; 1.7% of insider transactions were buys, 0.4% were sells. Insiders added 155,898 net shares over six months, signaling confidence in the post-earnings setup.

The stock slid on the Q1 report, and normalized P/E over ten years is 15.7, above the current 12.2 multiple, suggesting the market expects margin pressure or slower loan growth. Short interest is 5.5% of float.

8. Banc of California, Inc. (BANC)

P/E: 14.4 | Earnings yield: 7.0% | 52w drawdown: 13.7%

The bank trades at 0.94× book with an 8.2% FCF yield and 2.6% dividend yield. Revenue grew 12%, and analysts hold a $23 target against a $19 current price, implying 21% upside. Q1 earnings showed margin expansion and deposit growth.

Insiders sold 12.6 million net shares over six months; 1.4% of transactions were buys, 91.8% were sells. CORSINI BRYAN M filed twice in late April, and BANK OF AMERICA CORP filed in early April, marking the dominant selling activity.

Short interest is 6.5% of float, and the stock is up only 20 basis points over the trailing year. Debt-to-equity is 0.99, in line with regional bank norms, but the insider selling pattern flags management rotation or liquidity events rather than conviction.

What to Watch

INCY earnings (expected early May): The Jakafi XR approval shifts the focus to commercial execution and pipeline updates; watch for guidance on peak sales and patent strategy.
FSLR solar tariff resolution (ongoing): Any clarity on U.S. trade policy or module pricing will move the stock more than quarterly results; the 25% drawdown is a policy discount waiting for a catalyst.
CNX infrastructure updates (Q2): The 49% revenue growth is tied to demand and pipeline buildout; any pullback in natural gas infrastructure spending breaks the thesis.
NEM gold price correlation (daily): The 30% ROIC and 19% drawdown are tied to spot gold holding above $3,200; a break below that level resets the margin outlook.

Go Deeper

The value screener surfaces companies trading below their earnings power, cash generation, or book value, with insider buying or analyst upside as confirming signals.

Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Stock Pixie Pro

See the full Buy the Dip screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial →

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.